{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:34:47Z","timestamp":1770413687302,"version":"3.49.0"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/iop.0b013e31824ab228","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T19:13:13Z","timestamp":1342811593000},"page":"e145-e146","source":"Crossref","is-referenced-by-count":7,"title":["Second-Line 90Yttrium-Ibritumomab Tiuxetan (Zevalin) in a Patient With Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma Refractory to Rituximab"],"prefix":"10.1097","volume":"28","author":[{"given":"Patrick","family":"Oellers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Savar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Esmaeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-43-20210129","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ajo.2008.03.013","article-title":"Ocular adnexal lymphoid tumors: progress in need of clarification.","volume":"145","author":"Jakobiec","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R2-43-20210129","first-page":"1225","article-title":"Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.","volume":"120","author":"Esmaeli","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R3-43-20210129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/annonc\/mdn692","article-title":"Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.","volume":"20","author":"Esmaeli","year":"2009","journal-title":"Ann Oncol"},{"key":"R4-43-20210129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/MNM.0b013e32832a6e4d","article-title":"Estimation of yttrium-90 Zevalin tumor-absorbed dose in ocular adnexal lymphoma using quantitative indium-111 Zevalin radionuclide imaging.","volume":"30","author":"Erwin","year":"2009","journal-title":"Nucl Med Commun"},{"key":"R5-43-20210129","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkins lymphoma.","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Ophthalmic Plastic & Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IOP.0b013e31824ab228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:50:14Z","timestamp":1620957014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002341-201211000-00043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/iop.0b013e31824ab228","relation":{},"ISSN":["0740-9303"],"issn-type":[{"value":"0740-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}